ProCE Banner Activity

CME

Approaches to Individualized Management of Patients with Myeloproliferative Neoplasms: Best Practices and Guidance to Optimize Care

Multimedia
Watch this CME-certified on-demand Webcast of a CCO live symposium from ASH 2019 to gain insights from the experts on best practices for the individualized care of patients with myeloproliferative neoplasms.

Physicians: Maximum of 2.50 AMA PRA Category 1 Credits

Released: January 17, 2020

Expiration: January 16, 2021

No longer available for credit.

Share

Faculty

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Alessandro M. Vannucchi

Alessandro M. Vannucchi, MD

Full Professor of Hematology
Department of Experimental and Clinical Medicine
University of Florence
Director
Center of Research and Innovation of Myeloproliferative Neoplasms
AOU Careggi
Florence, Italy

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

CTI BioPharma Corp

Geron

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with myeloproliferative neoplasms.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal, individualized treatment for patients with MPNs based on recent advances and evolving best practices to maximize clinical outcomes
  • Integrate emerging agents and regimens for MPNs into routine practice as clinically appropriate
  • Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs
  • Develop strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion
  • Refer appropriate patients with MPNs to select ongoing clinical trials of novel agents and strategies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received consulting fees from Celgene, Constellation, Incyte, Novartis, Sierra, and Pragmatist, and funds for research support from Blueprint Medicines Corp., Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte Corp., Novartis, NS Pharma, Promedior and Roche.

Faculty Disclosure

Primary Author

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit Rampal, MD, PhD, has disclosed that he has received consulting fees from Beyond Spring, Celgene, Constellation, Jazz, Partner Therapeutics, and Stemline and contracted research fees from Constellation and Stemline.

Alessandro M. Vannucchi, MD

Full Professor of Hematology
Department of Experimental and Clinical Medicine
University of Florence
Director
Center of Research and Innovation of Myeloproliferative Neoplasms
AOU Careggi
Florence, Italy

Alessandro M. Vannucchi, MD disclosed that he has received consulting fees from Incyte and Novartis, and fees for non-CME/CE services from Celgene.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 17, 2020, through January 16, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the treatment of patients with myeloproliferative neoplasms.